DGS Capital Management LLC Trims Stock Position in GSK plc (NYSE:GSK)

DGS Capital Management LLC lessened its stake in GSK plc (NYSE:GSK) by 19.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 30,225 shares of the pharmaceutical company’s stock after selling 7,238 shares during the quarter. DGS Capital Management LLC’s holdings in GSK were worth $1,120,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. FMR LLC grew its stake in GSK by 7.7% in the 3rd quarter. FMR LLC now owns 18,099,513 shares of the pharmaceutical company’s stock worth $656,107,000 after buying an additional 1,291,161 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in GSK by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,292,913 shares of the pharmaceutical company’s stock valued at $437,383,000 after buying an additional 673,419 shares during the last quarter. Primecap Management Co. CA raised its holdings in GSK by 2.4% during the 3rd quarter. Primecap Management Co. CA now owns 12,058,770 shares of the pharmaceutical company’s stock valued at $437,130,000 after buying an additional 287,000 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in GSK by 32.5% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 9,621,370 shares of the pharmaceutical company’s stock valued at $419,107,000 after buying an additional 2,362,274 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in GSK by 5.1% during the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock valued at $292,896,000 after buying an additional 389,871 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 1.2 %

Shares of NYSE:GSK traded down $0.49 during midday trading on Tuesday, reaching $40.01. The company’s stock had a trading volume of 1,192,550 shares, compared to its average volume of 3,505,435. The firm has a 50 day moving average of $42.07 and a 200-day moving average of $38.73. The firm has a market capitalization of $82.92 billion, a P/E ratio of 13.46, a PEG ratio of 1.86 and a beta of 0.64. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 1.19. GSK plc has a 12-month low of $33.33 and a 12-month high of $43.84.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, January 31st. The pharmaceutical company reported $0.72 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a net margin of 16.24% and a return on equity of 51.45%. The firm had revenue of $10 billion for the quarter, compared to analysts’ expectations of $9.79 billion. On average, research analysts anticipate that GSK plc will post 4.03 earnings per share for the current year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were paid a dividend of $0.3564 per share. The ex-dividend date was Thursday, February 22nd. This represents a $1.43 annualized dividend and a yield of 3.56%. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio is currently 52.82%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Morgan Stanley initiated coverage on shares of GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Finally, Citigroup upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy”.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.